Strategy for Neoplasm Prevention
To prevent tumor development, it is necessary to minimize contact with carcinogens and increase overall bodily resistance.
Main directions of prevention:
- Prevention of carcinogen action. The primary task is to protect the cell genome from mutations.
- Reduction of carcinogenic burden. This includes modernizing technologies in industry, agriculture, and daily life. In hazardous industries, personal protective equipment (specialized clothing, respirators, remote manipulators) is mandatory. Special attention is paid to protecting women during pregnancy and lactation to exclude blastomogenic effects on the fetus.
- Enhancing anti-blastomogenic resistance. Achieved through a healthy lifestyle: complete cessation of smoking and alcohol, regular physical activity and exercise, and a balanced diet.
- Elimination of preneoplastic conditions. Early detection of potentially dangerous pathologies is crucial. For example, timely treatment of cryptorchidism in boys prevents the development of germ cell testicular tumors, while removing teratomas before three months of age prevents their malignant transformation into teratoblastomas.
Four Principles of Antitumor Therapy
Medical care for patients with neoplasms relies on four fundamental principles:
- Etiotropic. Aims at inactivating and eliminating carcinogens from the body.
- Pathogenetic. Aims to disrupt key links of carcinogenesis and physically destroy or remove the tumor.
- Sanogenetic. Focuses on activating the tissue's own anti-blastomogenic mechanisms using adaptogens, immunomodulators, and immunostimulants.
- Symptomatic. Designed to alleviate distressing symptoms (e.g., pain syndrome) that worsen the patient's condition, using analgesics and tranquilizers.
Modern Pathogenetic Methods
Pathogenetic treatment is the basis of oncology, aiming to destroy the neoplasm. In addition to classical non-pharmacological methods (surgical, radiation, thermal) and standard polychemotherapy, modern targeted and immunologic agents are actively used:
- Telomerase inhibitors (primarily for treating leukemias) and apoptosis modulators.
- Cadherin expression regulators, which help limit the metastatic process.
- Cytokines (e.g., IL-2). They stimulate NK cell proliferation, enhance the synthesis of cytotoxic molecules that trigger target cell apoptosis, increase the number of surface receptors, and accelerate the migratory potential of immunocompetent cells.
- Cellular adoptive therapy. The patient's immune cells (macrophages, T lymphocytes, NK cells) are isolated, their killer activity is enhanced ex vivo using leukokines or tumor cells, and they are then reinfused into the body. This provides a significant cancerolytic effect. Examples include LAK cells (IL-2-activated NK cells), TIL cells (a mixture of NK cells and tumor tissue cells), and CIK cells.
- Immune checkpoint inhibitors. Monoclonal antibody-based drugs block inhibitory signals (B7-CTLA-4 interaction or PD1 receptors). This removes the "brakes" from the immune system and sharply increases the killer effect of T lymphocytes and NK cells.
Approaches to Patient Management Tactics
The choice of specific tactics is always strictly individualized. The physician considers the type and histological structure of the tumor, the stage of development, the presence of metastases, as well as the patient's sex, age, and comorbidities.
Globally, two approaches to differentiated treatment are distinguished:
- Radical intervention. Aims at the complete elimination of the tumor. The expected outcome is complete recovery or long-term remission.
- Palliative treatment. Used under strict indications when radical therapy is impossible (e.g., in late stages of tumor progression).
- Comprehensive therapy yields the best results, combining various modalities: surgery, radiation therapy, chemotherapy, immunotherapy, and genetically engineered selective antitumor agents.